• Milestone backed by the largest body of clinical evidence in category as ophthalmology community convenes at ASCRS 2026¹⁻⁵
  • TECNIS Eyhance IOL delivers proven intermediate capabilities with monofocal-like distance quality and superior image contrast day and night³⁻⁵

Johnson & Johnson today announced that TECNIS Eyhance intraocular lens (IOL), the industry’s first enhanced monofocal IOL, has now been implanted in more than 10 million eyes globally⁷, reinforcing its position as the established market leader in the enhanced monofocal category.

As cataract surgeons continue to seek technologies that meet growing patient expectations for intermediate vision without compromising distance clarity, TECNIS Eyhance IOL stands apart as the most clinically validated and widely adopted solution in the category it created.²,⁶,⁷

“Reaching over 10 million implants is not just a volume milestone, it is validation that TECNIS Eyhance IOL delivers consistent, real-world outcomes at scale,” said Paul Lisenby, Global Head of R&D, Vision, Johnson & Johnson. “That level of adoption reflects years of clinical evidence, surgeon trust, and performance under everyday visual conditions.”⁷

A Category Defining Innovation with Proven Staying Power

Since its global introduction, TECNIS Eyhance IOL has transformed expectations for monofocal lenses by delivering enhanced intermediate vision while preserving monofocal-like distance quality and image contrast, day and night.³⁻⁵ Unlike other market options supported primarily by early optical modeling, TECNIS Eyhance IOL is backed by extensive clinical evidence across diverse patient populations and real-world practice settings.¹⁻⁵

Clinical Performance That Translates Clearly to Patients and Surgeons

Built on the trusted TECNIS platform—celebrating more than 25 years of use in ophthalmology—TECNIS Eyhance IOL extends depth of focus through a continuous increase in power while maintaining high quality distance vision.³⁻⁵

What the data shows:
• Superior intermediate visual acuity versus standard monofocal lenses, without tradeoffs in distance vision⁴⁻¹¹
• Additional line of visual acuity at 1.5 diopters of defocus compared with standard monofocals⁴
• Exceptional low-light image contrast, with optical bench testing demonstrating >31% higher image contrast versus Clareon monofocal lenses under clinically relevant white light conditions⁵
• Monofocal-like visual quality, supported by optical design that corrects spherical aberration to essentially zero³,¹⁴⁻¹⁶

TECNIS Eyhance IOL is part of the industry leading TECNIS platform, combining advanced optics with proprietary material. The TECNIS portfolio also includes TECNIS PureSee IOL, a purely refractive EDOF IOL17 and TECNIS Odyssey IOL, a Full Visual Range (FVR) IOL18. Johnson & Johnson will present new data on TECNIS PureSee IOL and TECNIS Odyssey IOL at ASCRS 2026.

For more patient information and tools please visit www.clearvisionforyou.com. Visit us at jnjvisionpro.com/en-us/ and follow Johnson & Johnson | Vision on LinkedIn.

INDICATIONS and IMPORTANT SAFETY INFORMATION for TECNIS Eyhance™ IOL

Rx Only

INDICATIONS FOR USE

ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information

About Vision at Johnson & Johnson

Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on X, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.

About Johnson & Johnson 

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US/. Follow us at @JNJMedTech on LinkedIn.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TECNIS Eyhance IOL. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

©Johnson & Johnson and its affiliates 2026. All rights reserved.

###

  1. 2025PP04126 – TECNIS Eyhance™ Playbook
  2. 2025PP05089 – TECNIS Eyhance™ and TECNIS Eyhance™ Toric II IOL Compendium 2024 – US
  3. TECNIS Eyhance™ DFU Z311769E Rev C
  4. Data on file DOF2021CT4006, TECNIS Eyhance™ Simulated Visual Acuity
  5. DOF2018OTH4004 – Data on file., TECNIS Eyhance™ IOL Monofocal Competitors MTF
  6. 2025REF4815. 2025 Market Scope Global IOL Report, pg. 92
  7. 2026REF4047 – 10MM TECNIS Eyhance™ implants worldwide
  8. REF2023CT4456 – Visual Outcomes and Patient Satisfaction after Bilateral Implantation of an Enhanced Monofocal Intraocular Lens: A Single-masked Prospective Randomized Study – R Giglio, AL Vinciguerra, et al. – Int J Ophthal 2023
  9. 2026REF4635 – Alcon website: https://www.myalcon.com/cataracts/clareon-iols/monofocal/
  10. 2026REF4636 JPMorgan Healthcare Conference: Alcon Presentation
  11. REF2023CT4456 – Visual Outcomes and Patient Satisfaction after Bilateral Implantation of an Enhanced Monofocal Intraocular Lens: A Single-masked Prospective Randomized Study – R Giglio, AL Vinciguerra, et al. – Int J Ophthalmol 2023
  12. TECNIS Eyhance™ Toric II IOL with TECNIS SIMPLICITY™ Delivery System DFU, Z311770E Rev. C
  13. Data On File. DOF2018CT4007, Chromatic Aberration of TECNIS Symfony™ IOL
  14. TECNIS™ 1 Piece IOL DFU Z311480, current revision
  15. Eppig T, et al. Aberration Correction with Aspheric Intraocular Lenses. Intechopen. 14 Oct 2019. 2024REF5180
  16. Altmann GE. Wavefront-customized intraocular lenses. Curr Opin DOF2021CT4002Opthalmol. 15 August 2004 2024REF6783
  17. TECNIS PureSee™ IOL with TECNIS SIMPLICITY™ Delivery System, Model DEN00V US DFU Z312075E rev B.
  18. TECNIS Odyssey IOL with TECNIS SIMPLICITY Delivery System, Model DRN00V. Directions for Use, current revision.